Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

VERTEX ORAL ANTI-INFLAMMATORY DRUG R&D PROGRAM WILL RECEIVE UP TO $30 MIL.

Executive Summary

VERTEX ORAL ANTI-INFLAMMATORY DRUG R&D PROGRAM WILL RECEIVE UP TO $30 MIL. from Roussel Uclaf for compounds targeting the interleukin-1 beta converting enzyme, the companies announced Sept. 9. Under the agreement, the French firm Roussel Uclaf will provide the Vertex Inflammation Program, begun in 1991, with 15-30 researchers and up to $30 mil. in milestone and calendar payments for orally active drugs for inflammatory diseases. In exchange, Roussel Uclaf gains exclusive European rights to develop and commercialize drugs resulting from the joint project. Cambridge, Mass.-based Vertex Pharmaceuticals retains exclusive rights in the U.S., Central and South America. Vertex and Roussel Uclaf will copromote any successfully commercialized drug products in Europe and the Americas and will share rights to develop and market the drugs in the Far East, including Japan. Vertex said research into IL-1 beta is in the beginning stages. The company does not expect preclinical trials to begin before 1995. In addition to the R&D funding, the active participation of Roussel Uclaf researchers brings the French firm's expertise in animal pharmacology and medicinal chemistry, Vertex said. Vertex' field of specialization is X-ray crystallography applied to rational drug design. The Roussel Uclaf collaborative program is the second announced by Vertex in 1993. In April, Vertex signed an R&D agreement with the Japanese firm Kissei Pharmaceutical to fund its oral AIDS drug program ("The Pink Sheet" April 19, T&G-12). Under that agreement, Kissei will provide technical assistance and will pay Vertex up to $20 mil. in research funding and milestone payments over three years related to compounds targeting HIV protease enzyme inhibitors. Vertex also has a five-year immunophilins R&D program with Chugai Pharmaceuticals established in October 1990.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS023315

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel